[go: up one dir, main page]

GB2128630A - Method of affinity purification employing monoclonal antibodies - Google Patents

Method of affinity purification employing monoclonal antibodies

Info

Publication number
GB2128630A
GB2128630A GB08332644A GB8332644A GB2128630A GB 2128630 A GB2128630 A GB 2128630A GB 08332644 A GB08332644 A GB 08332644A GB 8332644 A GB8332644 A GB 8332644A GB 2128630 A GB2128630 A GB 2128630A
Authority
GB
United Kingdom
Prior art keywords
monoclonal antibodies
affinity purification
antibodies
antigens
environment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08332644A
Other versions
GB8332644D0 (en
GB2128630B (en
Inventor
Richard M Bartholomew
Daniel E Beidler
Gary S David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of GB8332644D0 publication Critical patent/GB8332644D0/en
Publication of GB2128630A publication Critical patent/GB2128630A/en
Application granted granted Critical
Publication of GB2128630B publication Critical patent/GB2128630B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Process for affinity purification of antigens and antibodies that employs monoclonal antibodies having a high affinity for the antigen in a first environment and a low affinity in a second environment, the environments being ones in which the immuno-chemical properties of the antigens and antibodies are not adversely affected. Also described is a process for fractionating antisera to obtain an antibody fraction having similar antigen binding properties as exhibited by the environmentally sensitive monoclonal antibodies. The effect of varying pH in the binding capability of tow monoclonal antibodies for human growth hormone is shown in fig. 1.
GB08332644A 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies Expired GB2128630B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778182A 1982-04-12 1982-04-12
PCT/US1983/000524 WO1983003678A1 (en) 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies

Publications (3)

Publication Number Publication Date
GB8332644D0 GB8332644D0 (en) 1984-01-11
GB2128630A true GB2128630A (en) 1984-05-02
GB2128630B GB2128630B (en) 1986-08-28

Family

ID=23448565

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08332644A Expired GB2128630B (en) 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies

Country Status (11)

Country Link
EP (1) EP0105359A4 (en)
AT (1) AT393386B (en)
AU (1) AU622099B2 (en)
CA (1) CA1209907A (en)
CH (1) CH672028A5 (en)
DK (1) DK192191A (en)
ES (3) ES521371A0 (en)
FI (1) FI88403C (en)
GB (1) GB2128630B (en)
IT (1) IT1219779B (en)
WO (1) WO1983003678A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) * 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
GB8331071D0 (en) * 1983-11-22 1983-12-29 Karayiannis P Assay for dna/rna
US4666865A (en) * 1984-01-13 1987-05-19 Centocor, Inc. Immunoassay for biologically active human interferon-gamma employing unique monoclonal antibodies
US4789631A (en) * 1984-02-17 1988-12-06 Synbiotics Corporation Immunoassay for anti-dirofilaria immitis antibody
GB8426468D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU5259786A (en) * 1985-01-30 1986-08-07 United States Of America, The Monoclonal antibodies against chlamydial genes specific lipopolysaccharide
US4818687A (en) * 1985-02-28 1989-04-04 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4859611A (en) * 1985-02-28 1989-08-22 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
IL75828A (en) * 1985-07-17 1991-06-10 Univ Ramot Immobilization by biologically active proteins
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
SE468653B (en) * 1987-03-06 1993-02-22 Perstorp Biolytica ADSORBENT FOR ISOCRATIC AFFINITY CHROMATOGRAPHY
JPS6463599A (en) * 1987-05-01 1989-03-09 Xoma Corp Purification of immunoglobulin by selective anti-idiotype bond
DE3871799D1 (en) * 1987-07-14 1992-07-09 Univ Manchester METHOD FOR DIAGNOSIS OF INFECTIONS IN WHICH LIPOPOLYSCACCHARIDANTIGENS ARE DETERMINED.
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
CA2266341A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
UA121453C2 (en) * 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
JP6227191B1 (en) 2014-12-19 2017-11-08 中外製薬株式会社 Anti-myostatin antibody, polypeptide comprising mutant Fc region, and method of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CN110724204B (en) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Purification method of Fc fusion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
ATE14269T1 (en) * 1981-02-26 1985-08-15 Unilever Nv METHOD AND DEVICE FOR RECOVERING IMMUNOGLOBULINES.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
ES528000A0 (en) 1985-08-01
FI88403B (en) 1993-01-29
CH672028A5 (en) 1989-10-13
FI834530L (en) 1983-12-09
IT1219779B (en) 1990-05-24
EP0105359A4 (en) 1984-08-20
ES8506902A1 (en) 1985-08-01
ES8404858A1 (en) 1984-05-16
IT8320550A0 (en) 1983-04-12
FI88403C (en) 1993-05-10
GB8332644D0 (en) 1984-01-11
ES8706964A1 (en) 1987-07-01
CA1209907A (en) 1986-08-19
WO1983003678A1 (en) 1983-10-27
DK192191D0 (en) 1991-11-26
DK192191A (en) 1991-11-26
EP0105359A1 (en) 1984-04-18
ES528001A0 (en) 1987-07-01
ATA901983A (en) 1991-03-15
AU7256987A (en) 1987-09-03
GB2128630B (en) 1986-08-28
ES521371A0 (en) 1984-05-16
FI834530A0 (en) 1983-12-09
AT393386B (en) 1991-10-10
AU622099B2 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
GB2128630A (en) Method of affinity purification employing monoclonal antibodies
AU549077B2 (en) Determination of antigens with monoclonal antibodies
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
EP0098162A3 (en) Monoclonal antibodies specific to carcinoembryonic antigen
GB2114289B (en) Immunoassay for class specific immunoglobulin antibodies
PT83894A (en) Monoclonal antibodies cross-reactive and cross-protective against p aeroginosa serotypes
AU564575B2 (en) Polyvalent endotoxin specific antibodies
AU567681B2 (en) Immunoassay involving monoclonal igm antibody
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
CA2054689A1 (en) An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
EP0245509A4 (en) Method of immunoassay.
DE3273844D1 (en) Procedure for immunological determinations using two antibodies, the second antibody being purified by affinity chromatography, and supports therefor
ES546594A0 (en) A PROCEDURE FOR PREPARING AN ANTI-UROCINASE MONOTIONAL ANTIBODY.
DK329789A (en) MONOCLONAL ANTIBODY
EP0186371A3 (en) Monoclonal antibodies specific to antigens of hepatitis b virus
AU546797B2 (en) Monoclonal antibodies against tumor antigens and method
FI813796A7 (en) Immunoassay method and device for determining components such as antigens or antibodies.
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan
DE3174878D1 (en) Immunoassay utilizing monoclonal high affinity igm antibodies
IT8821547A0 (en) IMMUNOLOGICAL METHOD FOR THE DETERMINATION OF ANTIBODIES TO ANTIGENS OF MICROORGANISMS, USING ANTIIDIOTYPE ANTIBODY AND MEANS SUITABLE FOR THE PURPOSE.
CA2178504A1 (en) Immunoassays for prostate specific antigen

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19930412